Skip to content

The Risk of Infections in Multiple Myeloma in the Era of Novel Agents

4:23 min Published on 01-01-2024

Despite the emergence of novel agents to treat multiple myeloma therapies, infections are still a major cause of morbidity and mortality for patients. Discover Dr. Cecilie Blimark’s work assessing risks of viral, bacterial, and fungal infections in 8672 patients from the Swedish Myeloma Registry compared to 34,567 matched controls.

Blimark C et al., Blood 2023;142:4696-4698;Abstract

NX-BE-MMU-VID-240001